Berry Street Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Berry Street Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-71,875	Closed	-$6.35M	–	74
2021 Q4	$6.35M	Buy	71,875 +15,625	+28%	+$1.29M	0.65%	36
2021 Q3	$4.35M	Buy	56,250 +6,250	+13%	+$493K	0.66%	33
2021 Q2	$4.17M	Buy	50,000 +12,500	+33%	+$991K	0.37%	39
2021 Q1	$2.83M	Buy	+37,500	New	+$3.06M	0.31%	46

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Berry Street Capital Management's BMRN Position: Q1 2022 in Review

Berry Street Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 71,875 shares — an estimated $6.35M sold.

Berry Street Capital Management first reported a position in BMRN in Q1 2021 and held it in 4 quarters. The position peaked at $6.35M in Q4 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Berry Street Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Berry Street Capital Management sold 71,875 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $6.35M.
Berry Street Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Berry Street Capital Management's BioMarin Pharmaceuticals position peaked at $6.35M in Q4 2021.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Berry Street Capital Management's 13F filing for Q1 2022, filed 13 May 2022.